Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18606894 | 0.89 | KDM1A (0.40) | — | |
| SCHEMBL18555559 | 0.81 | CHRM3 (0.31) | CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL18582039 | 0.80 | PRKCG (0.32) | CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL18581645 | 0.80 | BACE1 (0.30) | SMN1; SMN2 | |
| SCHEMBL22230101 | 0.80 | SMN1; SMN2 (0.31) | CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL18581394 | 0.79 | — | — | |
| SCHEMBL17187996 | 0.78 | SSTR4 (0.36) | — | |
| SCHEMBL17187995 | 0.78 | SSTR4 (0.36) | — | |
| SCHEMBL4354026 | 0.76 | ACACB (0.34) | — | |
| SCHEMBL22227918 | 0.76 | L3MBTL1 (0.38) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046697-B2 | Compounds and compositions useful for treating disorders related to NTRK | BLUEPRINT MEDICINES CORPORATION | 2021-06-29 | — | — | US | disclosed |
| US-20190169194-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO NTRK | BLUEPRINT MEDICINES CORPORATION | 2019-06-06 | — | — | US | disclosed |
| US-10017512-B2 | Compounds and compositions useful for treating disorders related to NTRK | BLUEPRINT MEDICINES CORPORATION (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170066773-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO NTRK | BLUEPRINT MEDICINES CORPORATION | 2017-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066773-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO NTRK | NTRK2, NTRK3, NTRK1 | CYP3A4 4865/4885HTT 109/4885SMN1; SMN2 5/4885 |
| US-10017512-B2 | Compounds and compositions useful for treating disorders related to NTRK | NTRK3, NTRK2, NTRK1 | CYP3A4 4857/4885HTT 521/4885SMN1; SMN2 5/4885 |
| US-11046697-B2 | Compounds and compositions useful for treating disorders related to NTRK | NTRK3, NTRK2, NTRK1 | CYP3A4 4857/4885HTT 521/4885SMN1; SMN2 5/4885 |
| US-20190169194-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO NTRK | NTRK3, NTRK2, NTRK1 | CYP3A4 4857/4885HTT 521/4885SMN1; SMN2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.